12:00 AM
 | 
Mar 06, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Coagulin-B: Phase I

AVGN researchers and colleagues published in Nature Genetics results from the first 3 patients in a dose-escalation Phase I study, all of whom received 2(1011) vector genomes/kg by intramuscular injection. Modest...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >